日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发和/或难治性多发性骨髓瘤的真实世界疗效

Chen, Wenting; You, Jianhua; Lin, Li'e; Yan, Xiaojing; An, Gang; Wang, Yafei; Tian, Weiwei; Ding, Kaiyang; Zhang, Xi; Chen, Wenming; Wang, Yingxue; Fang, Baijun; Liu, Jing; Xia, Weilin; Feng, Zhaoyi; Zhou, Lei; Wang, Zhini; Shen, Dan; Liu, Gang; Zhao, Weili

Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs

淋巴瘤信号通路靶向治疗:从分子机制到临床突破

Wang, Shuqi; Qiu, Yuran; Zhao, Weili

Aluminum-Foil/Polyester Core-Spun Yarns Conductive Fabric Enabling High Electromagnetic Interference Shielding

铝箔/聚酯包芯纱线导电织物,可实现高电磁干扰屏蔽

Sun, Yanyan; Han, Xiaoyu; Zhao, Kun; Zhao, Weili; He, Zhitong; He, Zhengyang; Mo, Yingtie; Chu, Changliu; Natsuki, Toshiaki; Natsuki, Jun

Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.

普利诺他甲磺酸盐(一种新型选择性 HDAC I/IIb 抑制剂)在复发/难治性多发性骨髓瘤和淋巴瘤中的临床前和首次人体试验

Yang Linyu, Qiu Qiang, Wang Jie, Wen Yi, Li He, Liang Rui, Feng Yunyu, Wang Fang, Lin Xiaojing, Tang Minghai, Yang Jianhong, Pei Heying, Zhao Peng, Wang Jishi, Xiang Jin, Miao Jia, Zheng Li, Tan Ke, Wang Yongsheng, Hu Yiguo, Chen Lijuan, Zhao Weili, Niu Ting

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial

Tifcemalimab 单药治疗或联合 toripalimab 治疗复发/难治性淋巴瘤患者:一项 I 期试验

Song, Yuqin; Ma, Jun; Zhang, Huilai; Xie, Yan; Peng, Zhigang; Shuang, Yuerong; Li, Fei; Li, Yufu; Yang, Haiyan; Zou, Liqun; Sun, Xiuhua; Zhao, Weili; Huang, Wenrong; Huang, Yunhong; Zhou, Hui; Wang, Yifan; Wang, Weiwei; Xu, Jing; Deng, Rong; Meng, Qin; Zhu, Jun

Mechano-crosstalk between living and artificial cells.

活细胞与人工细胞之间的机械相互作用

Yu Xiaolei, Mukwaya Vincent, Wang Li, Zhao Weili, Mann Stephen, Dou Hongjing

MRI-based Habitat Analysis for the Prediction of Progression-Free Survival in Primary Spinal Tumors

基于磁共振成像的生境分析在预测原发性脊柱肿瘤无进展生存期中的应用

Wang, Qizheng; Zhang, Yang; Wang, Tongyu; Chen, Yongye; Yan, Ruixin; Liu, Ke; Zhao, Weili; Hao, Dapeng; Su, Min-Ying; Lang, Ning

A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma

基于机器学习的滤泡性淋巴瘤POD24预测模型:中国滤泡性淋巴瘤研讨会的一项研究

Zha, Jie; Chen, Qinwei; Zhang, Wei; Jing, Hongmei; Ye, Jingjing; Liu, Huanhuan; Yu, Haifeng; Yi, Shuhua; Li, Caixia; Zheng, Zhong; Xu, Wei; Li, Zhifeng; Lin, Zhijuan; Ping, Lingyan; He, Xiaohua; Zhang, Liling; Xie, Ying; Chen, Feili; Sun, Xiuhua; Su, Liping; Zhang, Huilai; Yang, Haiyan; Zhao, Weili; Qiu, Lugui; Li, Zhiming; Song, Yuqin; Xu, Bing

Association of triglyceride-glucose-related indices with all-cause and cause-specific mortality in individuals with prediabetesss

甘油三酯-葡萄糖相关指标与糖尿病前期患者全因死亡率和特定原因死亡率的关联

Zhang, Liwen; Zhao, Weili; Zheng, Panpan; Huang, Fang; Zhang, Lili; Zhang, Yuxin; Xiu, Xian; Zhang, Pei; Liu, Zanchao; Liu, Lipeng

Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma

中国专家就CAR-T细胞疗法治疗淋巴瘤的多学科团队综合病例管理达成共识

Tu, Sanfang; Li, Ping; Mei, Heng; Liu, Yang; Hu, Yongxian; Liu, Peng; Zou, Dehui; Niu, Ting; Xu, Kailin; Wang, Li; Yang, Jianmin; Zhao, Mingfeng; Huang, Xiaojun; Wang, Jianxiang; Hu, Yu; Zhao, Weili; Wu, Depei; Ma, Jun; Qian, Wenbin; Han, Weidong; Li, Yuhua; Liang, Aibin